The U.S. has long been the promised land for pharmaceutical companies. The U.S. features many plusses for drug makers, including its status as the lone market among developed countries that doesn't regulate prescription drug prices, high drug utilization among the public, and easy flow of capital. The combination of positive factors has attracted resources from around the globe, as seen in European drug giants such as GlaxoSmithKline
In light of recent events, though, one might question whether the U.S. is so great for pharmaceutical giants. Merck
All of these developments make Eli Lilly's
For now, Eli Lilly's efforts seem fairly modest. However, given the disruptions in the U.S. market, more aggressive moves in Japan may be possible. What's more, regulatory changes in Japan should allow foreign companies to more easily acquire domestic Japanese firms. Eli Lilly's renewed focus on Japan could be just a beginning.
Fool contributor Brian Gorman is a freelance writer in Chicago. He does not own shares of any companies mentioned in this article.
More from The Motley Fool
3 Things to Watch When This Top-Performing 3D Printing Company Reports Q4 Earnings
The company behind the "best 3D printing stock" reports fourth-quarter earnings on Thursday, Feb. 8.
Tech Is Walking Away From Wearables
What we did and didn’t see at CES, and what that means for the biggest trends in the tech industry.
Nintendo Switch Is the Fastest-Selling Console in U.S. History
And it could be on pace to become the best-selling console ever. How has Nintendo worked this magic?